Maccura Biotechnology Co.Ltd (300463.SZ)
CNY 12.06
(0.08%)
CNY 12.06
(0.08%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.51 Billion CNY | -18.2% |
| 2022 | 1.95 Billion CNY | -15.18% |
| 2021 | 2.3 Billion CNY | 17.24% |
| 2020 | 1.96 Billion CNY | 17.81% |
| 2019 | 1.67 Billion CNY | 20.06% |
| 2018 | 1.39 Billion CNY | 31.36% |
| 2017 | 1.05 Billion CNY | 31.49% |
| 2016 | 805.37 Million CNY | 32.73% |
| 2015 | 606.77 Million CNY | 9.54% |
| 2014 | 553.92 Million CNY | 26.09% |
| 2013 | 439.29 Million CNY | 29.3% |
| 2012 | 339.75 Million CNY | 23.87% |
| 2011 | 274.27 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 349.83 Million CNY | -20.23% |
| 2024 Q2 | 299.81 Million CNY | -14.3% |
| 2024 Q3 | 384.92 Million CNY | 28.39% |
| 2023 Q4 | 438.57 Million CNY | 3.23% |
| 2023 Q1 | 374.22 Million CNY | -28.26% |
| 2023 Q2 | 362.79 Million CNY | -3.06% |
| 2023 Q3 | 424.85 Million CNY | 17.11% |
| 2023 FY | 1.6 Billion CNY | -18.2% |
| 2022 Q2 | 465.26 Million CNY | -7.5% |
| 2022 Q1 | 503.01 Million CNY | -8.77% |
| 2022 FY | 1.95 Billion CNY | -15.18% |
| 2022 Q4 | 521.67 Million CNY | 11.78% |
| 2022 Q3 | 466.68 Million CNY | 0.3% |
| 2021 Q1 | 644.74 Million CNY | 4.4% |
| 2021 Q4 | 551.37 Million CNY | -10.55% |
| 2021 FY | 2.3 Billion CNY | 17.24% |
| 2021 Q3 | 616.39 Million CNY | 24.73% |
| 2021 Q2 | 494.18 Million CNY | -23.35% |
| 2020 Q1 | 259.01 Million CNY | -39.94% |
| 2020 FY | 1.96 Billion CNY | 17.81% |
| 2020 Q4 | 617.58 Million CNY | 4.67% |
| 2020 Q3 | 589.99 Million CNY | 17.79% |
| 2020 Q2 | 500.89 Million CNY | 93.39% |
| 2019 Q4 | 431.22 Million CNY | -0.54% |
| 2019 Q3 | 433.54 Million CNY | 0.64% |
| 2019 Q2 | 430.77 Million CNY | 15.04% |
| 2019 FY | 1.67 Billion CNY | 20.06% |
| 2019 Q1 | 374.46 Million CNY | 1.39% |
| 2018 Q4 | 369.31 Million CNY | -1.09% |
| 2018 Q2 | 373.54 Million CNY | 35.95% |
| 2018 Q1 | 274.77 Million CNY | -18.7% |
| 2018 FY | 1.39 Billion CNY | 31.36% |
| 2018 Q3 | 373.38 Million CNY | -0.04% |
| 2017 Q1 | 195.72 Million CNY | -16.31% |
| 2017 Q2 | 247.5 Million CNY | 26.46% |
| 2017 FY | 1.05 Billion CNY | 31.49% |
| 2017 Q3 | 277.73 Million CNY | 12.21% |
| 2017 Q4 | 337.98 Million CNY | 21.69% |
| 2016 Q3 | 208.12 Million CNY | -5.15% |
| 2016 FY | 805.37 Million CNY | 32.73% |
| 2016 Q4 | 233.87 Million CNY | 12.37% |
| 2016 Q2 | 219.41 Million CNY | 52.42% |
| 2016 Q1 | 143.95 Million CNY | -16.52% |
| 2015 Q2 | 172.53 Million CNY | 47.05% |
| 2015 Q1 | 117.32 Million CNY | -25.78% |
| 2015 FY | 606.77 Million CNY | 9.54% |
| 2015 Q4 | 172.45 Million CNY | 19.38% |
| 2015 Q3 | 144.45 Million CNY | -16.27% |
| 2014 FY | 553.92 Million CNY | 26.09% |
| 2014 Q4 | 158.08 Million CNY | 20.59% |
| 2014 Q1 | 109.98 Million CNY | 0.0% |
| 2014 Q3 | 131.08 Million CNY | -15.3% |
| 2014 Q2 | 154.77 Million CNY | 40.72% |
| 2013 FY | 439.29 Million CNY | 29.3% |
| 2012 FY | 339.75 Million CNY | 23.87% |
| 2011 FY | 274.27 Million CNY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 4.15 Billion CNY | 63.595% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.72 Billion CNY | 44.478% |
| Dirui Industrial Co.,Ltd. | 669.29 Million CNY | -125.843% |
| Beijing Strong Biotechnologies, Inc. | 1.3 Billion CNY | -16.241% |
| Medicalsystem Biotechnology Co., Ltd. | 834.37 Million CNY | -81.161% |
| Guangzhou Wondfo Biotech Co.,Ltd | 1.72 Billion CNY | 12.349% |
| Guangdong Hybribio Biotech Co.,Ltd. | 662.35 Million CNY | -128.211% |
| BGI Genomics Co., Ltd. | 2.17 Billion CNY | 30.362% |
| Amoy Diagnostics Co., Ltd. | 871.54 Million CNY | -73.436% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 329.31 Million CNY | -359.003% |